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M A J O R A R T I C L E
End-Stage Liver Disease Is a Strong Predictor of Early
Mortality in Cryptococcosis
Andrej Spec,1 Krunal Raval,2 and William G. Powderly1
1Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, and 2Department of Medicine, St. Lukes Hospital, St. Louis, Missouri
Background. Cryptococcosis in the setting of end-stage liver disease (ESLD) has been associated with high mortality. We sought
to compare the outcome of cryptococcal disease in patients with ESLD to that of human immunodeﬁciency virus (HIV)-positive
patients and to those patients without HIV or ESLD.
Methods. We assembled a retrospective cohort of 232 consecutive cases of cryptococcosis in our institution, from 2002 to 2014,
inclusively. We analyzed the cases for comorbidities, type of infection, and survival. Data were analyzed with t tests, Fishers Exact test,
and Kaplan-Meyer analysis.
Results. Twenty-ﬁve (10.8%) patients with cryptococcal infection had concomitant ESLD; of these, 5 (20%) presented with peri-
tonitis. Most (17 of 25, 68%) did not have any other cause of immunocompromise that has been more classically associated with
cryptococcosis. Patients with ESLD had a signiﬁcantly higher mortality than HIV-positive patients and HIV-negative patients with-
out ESLD (HIVNE) (80% vs 13.6% and 22.7%, respectively; P < .001). In addition, fatal outcome in ESLD patients occurred more
rapidly than in HIVNE patients, with a median survival of 6 days (vs 17), despite a comparable time to diagnosis (6.2 vs 6.6 days).
Conclusions. Cryptococcosis is an important morbidity in patients with ESLD. Patients with ESLD who are infected with Cryp-
tococcus have a high and rapid mortality. This suggests that a high level of vigilance for cryptococcal infection should be kept in
patients with ESLD.
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Cryptococcosis is one of the most common and important inva-
sive fungal infections worldwide, infecting predominantly immu-
nocompromised patients. Known predisposing conditions
include receipt of an organ transplant, being positive for
human immunodeﬁciency virus (HIV), and other causes of im-
munocompromise, such as use of glucocorticoids [1, 2]. World-
wide, it is estimated that there are 1 million cases and 625 000
deaths annually due to cryptococcal meningitis in HIV-infected
individuals alone [3]. In the United States, other predisposing
conditions account for the majority of cases of cryptococcosis
[4], suggesting that the burden of disease is considerable.
Although considerable improvements have been made to
treatment, mortality associated with cryptococcosis is depen-
dent on the underlying predisposing condition [4, 5]. Several
studies have found a trend to improved survival amongst pa-
tients who are HIV positive and a worse outcome in patients
who are HIV negative and do not have a transplant [4, 6].
Cryptococcal infections have been previously associated with
end-stage liver disease (ESLD). Case reports of cryptococcal
infection as a complication of cirrhosis date back as far as at
least 1967 [7]. Mortality in these case reports exceeds 80%,
with 92% of the mortality attributed to the cryptococcal in-
fection [5]. In a recent review, “liver failure”, autoimmune
hepatitis, and ESLD have been associated with 6.1-, 10-, and
2.8-fold increase in relative prevalence of cryptococcal meningi-
tis compared with the general population, respectively [1].
Therefore, we evaluated the cases of cryptococcosis occurring
in a large tertiary care hospital from 2002 to 2014 with the




Data were collected from patients admitted to Barnes-Jewish
hospital, a 1315-bed tertiary referral hospital located in an
urban environment, with a signiﬁcant suburban and rural refer-
ral base. The study was approved by the Washington University
(St. Louis, MO) Institutional Review Board.
Cases of cryptococcosis from January 1, 2002 to December
31, 2015 were studied. Cases were identiﬁed by either a positive
cryptococcal antigen or a culture positive for Cryptococcus spp.
Due to limitations of the informatics system, cases of cryptococ-
cosis identiﬁed by histopathology alone could not be retrieved.
If histopathology was available in addition to antigen and
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culture, it was used for deﬁning location of disease. A standard-
ized data collection tool was used to collect data on age, sex, sur-
vival, immune status, presentations, laboratory, and treatment.
Patients were then divided into 3 separate groups: HIV+ pa-
tients, patients with ESLD, and HIV-negative without ESLD
(HIVNE). The patients who met criteria for both the HIV
and the ESLD group were classiﬁed in the ESLD group for
the purposes of data analysis.
Deﬁnitions
Sites of infection were classiﬁed as follows: (1) central nervous
system (CNS), deﬁned by presence of Cryptococcus by histology,
antigen, or culture within the meninges or brain parenchyma,
or a positive cerebrospinal ﬂuid culture or antigen for Crypto-
coccus; (2) pulmonary, deﬁned by microbiologic or histologic
isolation of Cryptococcus from the lung or presence of pulmo-
nary inﬁltrates compatible with cryptococcal disease (nodules,
interstitial pattern, lobar consolidation, and acute respiratory
distress syndrome) and isolation of Cryptococcus from another
source; (3) blood, which was deﬁned by a positive blood culture,
either on routine bacterial cultures or dedicated fungal culture;
and (4) other, deﬁned by histological or microbiologic isolation
of Cryptococcus from a source other than lung, blood, or CNS,
such as ascitic ﬂuid. Patients could have multiple locations of
infection; for example, a case of cryptococcemia and meningitis
would be classiﬁed as CNS and bloodstream.
The causes of possible immunocompromise examined were
as follows: HIV infection, solid organ transplant, hematopoietic
stem cell transplant, diagnosis of cancer, recent (<30 days) re-
ceipt of chemotherapy, diabetes, ESLD, and receipt of immuno-
suppressants (such as glucocorticoids, antimetabolites, and
monoclonal antibodies). End-stage liver disease was deﬁned if
a liver biopsy was performed and showed cirrhotic changes or
if there was evidence of nodularity and ﬁbrosis on ultrasound or
computed tomography and there was evidence of synthetic liver
dysfunction, as deﬁned by elevated bilirubin (>5.0 mg/dL) and
increased international normalized ratio (>1.5) on admission.
End-stage renal disease was deﬁned as receipt of renal
replacement therapy or persistent glomerular ﬁltration rate
≤10 mL/min in the 90 days before admission. Immunosup-
pression due to medications was deﬁned as receipt of cytotoxic
chemotherapy, antimetabolite, monoclonal antibody, or gluco-
corticoid (≥5 mg of prednisone equivalent) in the 30 days be-
fore diagnosis.
Time to diagnosis was deﬁned as the time from admission
until the time the cryptococcal antigen or culture results indi-
cating the presence of Cryptococcus or encapsulated yeast
were ﬁrst available. Worsening renal failure was deﬁned by at
least a doubling in creatinine. A worsening of clinical status
was deﬁned as a new transfer to a higher level of care (such
as intensive care unit), a new institution of vasopressors, or de-
crease in mean arterial pressure more than 15 mmHg.
Statistical Analysis
Data were stored in Microsoft Access, and statistics were per-
formed using SPSS V23 (IBM, Armonk, NY). Fisher’s exact
test and Students t test were used for the descriptive statistics
and crude mortality. For survival analysis, mortality past 90
days was censored, because it was deemed less likely to be relat-
ed to the cryptococcal infection and more related to the under-
lying disease. Survival analysis comparing ESLD patients to
HIVNE was performed using Kaplan-Meier survival analysis.
All statistical tests were 2-tailed and assessed signiﬁcance at
α = 0.05.
RESULTS
Two hundred forty-seven cases of possible cryptococcosis were
identiﬁed. Fifteen cases were excluded from analysis; 5 lacked
any clinical data, 3 represented false-positive antigen tests that were
of low titer, not repeatable, and the patients were not treated; and
7 were cases of non-neoformans Cryptococcus. This included
2 cases of Cryptococcus laurentii, 1 case each of Cryptococcus
luteolus, Cryptococcus albidus, Cryptococcus uniguttulatus, Cryp-
tococcus humicolus, and 1 non-neoformans Cryptococcus where
a species could not be identiﬁed. Ultimately, 232 cases were ana-
lyzed. Of those, 25 (10.8%) were classiﬁed as ESLD, 87 (37.5%) as
HIV, and 120 (51.7%) as HIVNE.
Baseline demographics were different between groups related
to the epidemiology of the underlying diseases (Table 1). The
ELSD and HIVNE groups were quite similar, but they differed
signiﬁcantly from the HIV group. The HIV-positive patients
were more likely to be African American (77.3%) vs ESLD
(16%) and HIVNE (12.6%). They were also younger, 41 vs
61.8 and 59.5 years, respectively.
Seventeen of 25 did not have another cause of immunocom-
promise classically associated with Cryptococcus. One patient
had both HIV and ESLD. The remaining 7 patients had multi-
ple additional causes of immunocompromise, including cancer,
chemotherapy, ESLD, renal and lung transplant, and receipt of
glucocorticoids, cyclosporine, mycophenolic acid, and tacroli-
mus (Table 2). All patients were classiﬁed in the ESLD group
regardless of other conditions. The mean time to diagnosis
was similar between the ESLD (6.2 days) and HIVNE (6.6
days) patients, but it was much more rapid in the HIV-positive
patients (2.2 days) (Table 1).
The percentage of patients with meningitis was similar be-
tween HIVNE (41.2%) and ESLD (44%) groups, but it was
much higher in HIV-positive patients (70.5%). Positive blood
cultures were more common in ESLD (56%) than in HIVNE
(33.6%), but they were comparable to the HIV patients (58%).
However, sites other than cerebrospinal ﬂuid, blood, and lungs
were much more common in ESLD patients (20%) compared
with HIVNE (6.7%) and HIV (2.3%) (Table 1). This was due
to positive peritoneal cultures in all 5 patients, and biopsy con-
ﬁrmed skin lesions in 1 patient.












The HIV-positive patients had the lowest 90-day mortality at
13.7%, followed by HIVNE (22.7%), in contrast to the 80%
mortality experienced in the ESLD group. This was signiﬁcant
(P < .001) when comparing ESLD group with HIVNE using
Kaplan-Meier analysis (Figure 1).
In addition to the overall mortality, the time to death in the
ESLD group was signiﬁcantly more rapid. The median survival
from admission in the HIV and HIVNE groups were 11 and 17
days, respectively, compared with 6 days in the ESLD group
(P < .001).
Amongst the patients with ESLD, 7 of 25 (28%) died before
administration of any antifungal therapy. Sixteen (64%) re-
ceived liposomal amphotericin B (LAB) and 13 of 16
(81.25%) of those that did died, with 11 of 16 (68.8%) dying
with at least a doubling in serum creatinine before death. The
2 patients who received ﬂuconazole for an isolated pulmonary
cryptococcosis survived.
Furthermore, patients with ESLD experienced a worsening in
their hemodynamic status. Of the 20 that died, 17 met at least 1
criterion for worsening clinical status. Fifteen had a decrease in
their mean arterial pressure (MAP) of more than 15 mmHG, 10
required a transfer to the intensive care unit (ICU), and 4 had a
new institution of vasopressors after starting therapy.
CONCLUSIONS
With the improvements in antiretroviral therapy over the last 20
years, there has been a shift in the epidemiology of cryptococcal
infection away from HIV as the predominant predisposing cause
Figure 1. Kaplan-Meier survival curve of 232 patients with cryptococcosis by un-
derlying condition, 2002–2014. Patients with end-stage liver disease (ESLD) had the
lowest survival, most dramatically expressed in the first 15 days of the infection.
Mortality was censored after 90 days because it was less likely to be related to
cryptococcosis; P < .001. Abbreviations: HIV, human immunodeficiency virus;
HIVNE, HIV-negative, without ESLD.
Table 1. Baseline Characteristics and Outcomes of 232 Patients With Cryptococcosis by Underlying Disease, 2002–2014
HIV N = 88 (%) ESLD N = 25 (%) HIVNE N = 119 (%) P Value Total Cohort N = 232 (%)
Mean age (±SD), years 41.0 (9.4) 61.8 (11.8) 59.5 (16.0) P < .001 52.7 (16.3)
Mean time to diagnosis (±SD), days 2.2 (7.0) 6.2 (9.6) 6.6 (11.5) P = .006 4.9 (9.9)
Male gender (%) 67 (76.1) 23 (92) 75 (63.0) P = .006 161 (71.1)
Race
White (%) 18 (20.5) 20 (80.0) 94 (79.0) P < .001 132 (56.9)
African American (%) 68 (77.3) 4 (16) 15 (12.6) P < .001 87 (37.5)
Other (%) 2 (2.3) 1 (4) 10 (8.4) P < .001 13 (5.6)
Site of Infection
CNS (%) 62 (70.5) 11 (44.0) 49 (41.2) P < .001 122 (52.6)
Pulmonary (%) 11 (12.5) 7 (28.0) 49 (41.2) P < .001 67 (28.9)
Bloodstream (%) 51 (58) 14 (56.0) 40 (33.6) P = .001 105 (45.3)
Other (%) 2 (2.3) 5 (20.0) 8 (6.7) P = .006 15 (6.5)
90-d mortality (%) 12 (13.6) 20 (80) 27 (22.7) P < .001 72 (31)
Abbreviations: CNS, central nervous system; ESLD, end-stage liver disease; HIV, human immunodeficiency virus; HIVNE, HIV-negative, without ESLD; SD, standard deviation.
Table 2. Other Comorbid Conditions of 232 Patients With Cryptococcosis
by Underlying Disease, 2002–2014
Immune Status
HIV
N = 88 (%)
ESLD
N = 25 (%)
HIVNE
N= 119 (%)
Immunocompetent 0 (0) 0 (0) 31 (26.1)
Pregnant 1 (1.1) 0 (0) 2 (1.7)
Chemotherapy 4 (4.5) 2 (8.0) 27 (22.7)
Solid Tumor 8 (9.1) 3 (12.0) 22 (18.5)
Hematologic Malignancy 0 (0) 1 (4.0) 23 (19.3)
Diabetes Mellitus 4 (4.5) 6 (24.0%) 22 (18.5)
End-Stage Renal Disease 4 (4.5) 2 (8.0) 8 (6.7)
Heart Transplant 0 (0) 0 (0) 4 (3.4)
Lung Transplant 0 (0) 2 (8.0) 7 (5.9)
Kidney Transplant 0 (0) 2 (8.0) 2 (1.7)
Liver Transplant 0 (0) 0 (0) 3 (2.5)
Bone Marrow Transplant 0 (0) 0 (0) 3 (2.5)
Graft-vs-Host Disease 0 (0) 0 (0) 2 (1.7)
Glucocorticoid Therapy 3 (3.4) 5 (20) 39 (32.8)
Biologic Therapy 0 (0) 2 (8.0) 9 (7.6)
Other Immunosuppressants 0 (0) 3 (12.0) 22 (19.1)
Abbreviations: ESLD, end-stage liver disease; HIV, human immunodeficiency virus; HIVNE,
HIV-negative, without ESLD.












in the United States [1]. Similar to our study, others have found
a trend to improved survival amongst patients who have HIV
infection, but none achieved statistical signiﬁcance [4, 6].
In particular, ESLD has emerged as an important risk factor
for developing cryptococcal meningitis [1]. Liver failure,
autoimmune hepatitis, and ESLD were associated with 6.1-,
10-, and 2.8-fold increase, respectively, in relative prevalence
of cryptococcal meningitis compared with the general popula-
tion [1]. In our data set, ESLD was present in 10.8% of the
cohort, and 68.0% of those patients had no other cause of
immunocompromise.
Decompensated ESLD in Taiwan was associated with an odds
ratio of 8.5 of developing cryptococcal meningitis and an odds
ratio of 23.8 of developing cryptococcemia compared with other
underlying conditions [8]. Patients with ESLD have been found to
have a 5.3-fold higher rate of dissemination than other non-HIV
patients [9]. Even after liver transplant, cryptococcosis appears to
have a higher risk of dissemination and a more severe presenta-
tion than patients with other solid organ transplants [10].
This increased risk may be related to previously demonstrat-
ed deﬁciencies in cell-mediated immunity amongst patients
with ESLD [11–13]. Liver functions as an important organ in
clearing infections because it contains the majority of the retic-
uloendothelial cells, and it is thus instrumental in clearing of cy-
tokines, bacteria, and endotoxin from the circulation [11]. A
total of 70%–96% of radiolabeled Gram-negative bacteria inject-
ed into healthy volunteers are localized to the liver within 10
minutes of injection [14]. The efﬁciency of this critical portion
of immunity is diminished by portosystemic shunting of blood.
In addition, monocyte, neutrophil, macrophage, and lympho-
cyte chemotaxis and function have been shown to be dimin-
ished in ESLD [11]. Patients with alcoholic liver disease have
a hyperactive B-cell response and a decreased lymphocyte trans-
formation [12] as well as a blunted T-cell response [13].
In addition to having an increased predisposition to crypto-
coccal infection, patients with ESLD have a much higher than
expected mortality. In our study, the overall mortality was 80%.
Furthermore, their mortality appears to be early in the course of
their disease, with a mean survival of only 6 days, despite a com-
parable time to diagnosis. In a case series of 5 patients, with a
systematic review of 28 cases in published literature [5], a similar
mortality of 81% (26 of 32) was observed. Of the 26 deaths, 24
(92%) were attributed to Cryptococcus [5]. In a recent multicen-
ter analysis of patients with cirrhosis and liver transplant, a
mortality of 57.1% was observed [15]. End-stage liver disease
was associated with a 7.5-fold increase in unsatisfactory out-
comes amongst patients infected with hepatitis B in China
[16] and a 100% mortality in a small Taiwanese cohort of 33
HIV-negative patients [17].
The ﬁndings of increased prevalence and early mortality
could be explained by several possible mechanisms. It is possi-
ble that patients with ESLD are infected by a different strain of
Cryptococcus due to their speciﬁc host immune defects. Howev-
er, we have no evidence to date that strain differences among C
neoformans contribute to outcome.
It is also possible that patients with ESLD are diagnosed very
late in the course of their disease due to low suspicion on the
part of the clinician. However, the time to diagnosis was same
in the ESLD group compared with HIVNE group (6.2 vs 6.6
days, respectively). This was much longer than the time to diag-
nosis in HIV+ patients (2.2 days), which is probably due to a
very high index of suspicion for cryptococcal disease in patients
living with HIV. Patients with ESLD were no more likely than
HIV patients to have a positive blood cultures and were no more
likely than HIVNE patients to have meningitis.
Mortality differences could be further explained by antifun-
gal toxicity in this patient group. Liposomal amphotericin B
and/or ﬂucytosine treatment may be too toxic in patients with
ESLD, because it can lead to renal or hepatic failure, which has a
high mortality in the setting of ESLD. Of the 16 patients with
ESLD who received LAB and ﬂucytosine, only 2 survived.
Of the 14 that died after receiving at least 1 dose of LAB, 11
(78.6%) died with at least a doubling in creatinine. This could
be related toworsening renal function from LAB toxicity. Awors-
ening of renal function has been observed in 66% of renal trans-
plant recipients infected with Cryptococcus who later developed
immune reconstitution inﬂammatory syndrome (IRIS) [18].
In our study, 15 patients had a decrease in their MAP of more
than 15 mmHG, 10 required a transfer to the ICU, and 4 had a
new institution of vasopressors after starting therapy. This raises
the possibility that treatment itself may trigger a response that
the precarious homeostatic balance in patients with ESLD is
rapidly worsened by the release of antigen during the treatment
with antifungal agents, resulting in hemodynamic instability,
reminiscent of a Jarisch-Herxheimer reaction. This has not
been demonstrated in other patient groups, but it may be
comparable to IRIS and warrants further study.
CONCLUSIONS
In conclusion, in our cohort of 232 patients with cryptococcosis
over 11 years, approximately 11% had underlying ESLD. In
these patients, the course of the disease is dramatically different,
because they exhibit much higher and more rapid mortality
compared with other populations. In view of the high and
rapid mortality in patients with ESLD, cryptococcosis should
be considered early in patients with ESLD presenting with
possible infection.
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